PMID- 35032826 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20240226 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 104 DP - 2022 Mar TI - Dendritic cell immunotherapy with miR-155 enriched tumor-derived exosome suppressed cancer growth and induced antitumor immune responses in murine model of colorectal cancer induced by CT26 cell line. PG - 108493 LID - S1567-5769(21)01129-2 [pii] LID - 10.1016/j.intimp.2021.108493 [doi] AB - Nowadays, various strategies are considered to prime Dendritic cells (DCs) with tumor antigens. The tumor cell-derived exosomes are recognized as one of the most efficient strategies for achieving this purpose. In this regard, MicroRNA 155 (miR-155) is employed as one of the most prominent miRNAs, which play substantial roles in DCs maturation and IL-12 production. This study investigates the tumor growth suppression and antitumor effects of DCs primed with miR-155-enriched exosome on the BALB/c murine model of colorectal cancer induced by CT-26 cell lines. Therefore, a holistic framework is proposed for the analysis procedure. In the first stage, miRNA-155 was electroporated into texosomes. In the second stage, bonemarrow-derived DCs were treated with miRNA-155 enriched texosomes. Then, antitumor properties of manipulated DC have been evaluated in the BALB/c mice model of colorectal cancer. After DC immunotherapy, several features have been assessed for each animal, including survival, body weight, tumor volume/size, histopathology, and serum cytokine levels. Also, flow cytometric evaluation has been performed for the spleen and the tumor tissue T-cell subsets. The findings demonstrated that the primed DCs could significantly increase IL-12p70 and IFN-gamma in serum and accelerate the differentiation, proliferation, and cytotoxicity effects on the Th and CTL cells. Also, the treatment also increased the infiltration of Th and CTL cells into the tumor microenvironment while decreasing Tregs. This situation causes tumor growth control, and survival improvement. Therefore, DC immunotherapywith miR-155-enriched texosomes can be employed as a the desired approach for inducing antitumor immune responses, controlling tumor growth, and improving survival in mice with colorectal cancer. However, it is essential to perform more investigations to confirm the clinical application of this approach in humans and other types of tumors. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Asadirad, Ali AU - Asadirad A AD - Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Cancer, Petroleum and Environmental Pollutants Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Baghaei, Kaveh AU - Baghaei K AD - Basic and Molecular Epidemiology of Gastrointestinal Disorder Research Center, Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Science, Tehran, Iran. FAU - Hashemi, Seyed Mahmoud AU - Hashemi SM AD - Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Dehnavi, Sajad AU - Dehnavi S AD - Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Ghanbarian, Hossein AU - Ghanbarian H AD - Cellular and Molecular Biology Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Mortaz, Esmaeil AU - Mortaz E AD - Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Anissian, Ali AU - Anissian A AD - Veterinary Pathology Department, Islamic Azad University, Abhar Branch, Abhar, Iran. FAU - Asadzadeh Aghdaei, Hamid AU - Asadzadeh Aghdaei H AD - Basic and Molecular Epidemiology of Gastrointestinal Disorder Research Center, Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Science, Tehran, Iran. FAU - Amani, Davar AU - Amani D AD - Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: amanid@sbmu.ac.ir. LA - eng PT - Journal Article DEP - 20220112 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (Cytokines) RN - 0 (MicroRNAs) RN - 0 (Mirn155 microRNA, mouse) SB - IM MH - Animals MH - Cell Line, Tumor MH - Colorectal Neoplasms/immunology/pathology/*therapy MH - Cytokines/blood/immunology MH - Dendritic Cells/*immunology MH - Disease Models, Animal MH - *Exosomes MH - Female MH - *Immunotherapy MH - Lymphatic Metastasis/immunology/pathology/therapy MH - Mice, Inbred BALB C MH - *MicroRNAs MH - Spleen/cytology/immunology MH - Tumor Burden MH - Mice OTO - NOTNLM OT - CT-26 OT - Colorectal cancer OT - Dendritic cell OT - Exosome OT - Immunotherapy OT - Mir-155 EDAT- 2022/01/16 06:00 MHDA- 2022/04/01 06:00 CRDT- 2022/01/15 20:20 PHST- 2021/10/18 00:00 [received] PHST- 2021/12/12 00:00 [revised] PHST- 2021/12/18 00:00 [accepted] PHST- 2022/01/16 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] PHST- 2022/01/15 20:20 [entrez] AID - S1567-5769(21)01129-2 [pii] AID - 10.1016/j.intimp.2021.108493 [doi] PST - ppublish SO - Int Immunopharmacol. 2022 Mar;104:108493. doi: 10.1016/j.intimp.2021.108493. Epub 2022 Jan 12.